Adicet Bio, Inc. (0HX7.L)
USD 0.67
(7.34%)
USD 0.67
(7.34%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 152.03 Million USD | 64.31% |
| 2022 | 92.53 Million USD | 37.91% |
| 2021 | 67.09 Million USD | 39.66% |
| 2020 | 48.04 Million USD | 54.26% |
| 2019 | 31.14 Million USD | -21.4% |
| 2018 | 39.62 Million USD | 109.91% |
| 2017 | 18.87 Million USD | 1887600.0% |
| 2016 | 1000.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 32.84 Million USD | 12.42% |
| 2024 Q1 | 29.22 Million USD | -2.2% |
| 2023 Q1 | 31.5 Million USD | 5.78% |
| 2023 FY | 126.47 Million USD | 36.69% |
| 2023 Q4 | 29.87 Million USD | -1.89% |
| 2023 Q3 | 30.45 Million USD | -6.61% |
| 2023 Q2 | 32.6 Million USD | 3.49% |
| 2022 FY | 92.53 Million USD | 37.91% |
| 2022 Q4 | 29.78 Million USD | 36.51% |
| 2022 Q2 | 21.64 Million USD | 12.22% |
| 2022 Q1 | 19.28 Million USD | -5.07% |
| 2022 Q3 | 21.81 Million USD | 0.81% |
| 2021 FY | 67.09 Million USD | 39.66% |
| 2021 Q2 | 14.49 Million USD | -11.43% |
| 2021 Q4 | 20.31 Million USD | 27.56% |
| 2021 Q1 | 16.36 Million USD | 12.54% |
| 2021 Q3 | 15.92 Million USD | 9.91% |
| 2020 Q2 | 16.11 Million USD | 69.86% |
| 2020 Q1 | 9.48 Million USD | 6.52% |
| 2020 FY | 48.04 Million USD | 54.26% |
| 2020 Q4 | 14.53 Million USD | -18.81% |
| 2020 Q3 | 17.9 Million USD | 11.12% |
| 2019 Q3 | 8 Million USD | 31.41% |
| 2019 FY | 31.14 Million USD | -21.4% |
| 2019 Q1 | 7.04 Million USD | 0.0% |
| 2019 Q2 | 6.09 Million USD | -13.53% |
| 2019 Q4 | 8.9 Million USD | 11.23% |
| 2018 FY | 39.62 Million USD | 109.91% |
| 2017 FY | 18.87 Million USD | 1887600.0% |
| 2016 FY | 1000.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| uniQure N.V. | 285.08 Million USD | 46.669% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -213.467% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -1152.269% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 62.809% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 44.852% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -6.721% |
| Imunon, Inc. | 21.03 Million USD | -622.943% |
| Dynavax Technologies Corporation | 219.14 Million USD | 30.622% |
| Editas Medicine, Inc. | 247.3 Million USD | 38.522% |
| FibroGen, Inc. | 398.11 Million USD | 61.81% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 66.288% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -288.318% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 90.477% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 88.827% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 71.26% |
| Verastem, Inc. | 92.08 Million USD | -65.108% |
| Zoetis Inc. | 2.76 Billion USD | 94.501% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 96.816% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 33.515% |
| Homology Medicines, Inc. | 9.87 Million USD | -1439.625% |
| Nektar Therapeutics | 190.9 Million USD | 20.359% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -50.791% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -240.381% |
| Perrigo Company plc | 1.52 Billion USD | 90.053% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 44.083% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.626% |
| Illumina, Inc. | 3.81 Billion USD | 96.013% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 98.517% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 92.594% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -26.008% |
| Waters Corporation | 943.51 Million USD | 83.886% |
| Biogen Inc. | 5.2 Billion USD | 97.079% |
| Evolus, Inc. | 189.75 Million USD | 19.878% |
| bluebird bio, Inc. | 240.23 Million USD | 36.712% |
| Geron Corporation | 70.44 Million USD | -115.837% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 91.554% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 64.448% |
| Myriad Genetics, Inc. | 600.1 Million USD | 74.665% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 72.435% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 86.044% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -993.04% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 91.294% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 94.6% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 92.811% |
| OPKO Health, Inc. | 574.68 Million USD | 73.544% |
| Exelixis, Inc. | 1.58 Billion USD | 90.418% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 58.754% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -172.685% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 68.083% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 80.498% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 49.205% |
| Blueprint Medicines Corporation | 722.86 Million USD | 78.967% |
| Insmed Incorporated | 949.26 Million USD | 83.984% |
| TG Therapeutics, Inc. | 198.47 Million USD | 23.397% |
| Incyte Corporation | 1.19 Billion USD | 87.229% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 85.437% |